Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 10 | Mind Blowing Facts

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times from 10 to 12 months…

Benzinga

Trump announces plan to lower cost of IVF drugs

The effort would pair two Trump priorities: lowering drug prices and making IVF treatment more affordable.

Axios

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market

BofA Securities initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA), ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday

U.S. stocks were higher, with the Nasdaq Composite gaining more than 50 points on Thursday.

Benzinga

Praxis Precision Medicines Stock Doubles - Here's Why

Praxis Precision Medicines Inc. (NASDAQ:PRAX) stock skyrocketed on Thursday.

Benzinga

Why Mira Pharmaceuticals Shares Rose 69% After Hours?

Mira Pharmaceuticals Inc. (NASDAQ:MIRA) shares jumped 68.94% to $2.23 in after-hours trading on Wednesday.

Benzinga

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

PPE Medpro fails to meet deadline to repay Government almost £122m after ruling

Mrs Justice Cockerill previously ruled that PPE Medpro had breached a contract for millions of surgical gowns during the coronavirus pandemic.

Evening Standard

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Benzinga

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.

Benzinga

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.

Benzinga

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However,…

Benzinga

Chronic Drug Shortages Frustrate EU Pharmacists, Patients

At a drug wholesaler warehouse in Belgium, shelves are emptier than they used to be.

International Business Times

Prescription drug coverage options are shrinking for Medicare shoppers

Fewer choices may be on the menu again as Medicare patients shop for prescription coverage this fall

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

TikTok influencers fuelling parallel market for unlicensed weight-loss drug

Guardian finds a thriving trade on Telegram for retatrutide, which is still in clinical trials and illegal to sell

The Guardian - US

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

Evening Standard

PPE Medpro partners willing to discuss ‘possible settlement’ of Covid gowns case

The Baroness Michelle Mone-linked company was ordered to pay back nearly £122 million due to a breach of contract

Benzinga

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments

UK ministers are preparing to increase the amount the National Health Service pays pharmaceutical firms for medicines by up to 25%, following weeks of intensive discussions with the Trump administration and drugmakers.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive week-on-week percentile gains.

Benzinga

Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading?

Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) saw its stock fall 3.67% to $10.50 during after-hours trading on Thursday.

Benzinga

4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs. Here’s a look at four stocks flashing strong momentum signals.

Benzinga

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

The Trump administration is reportedly planning to exclude imported generic drugs from tariffs.

Benzinga

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.

Benzinga

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug

Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

347 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.